Abstract
Increased ventricular volume enhances the systolic performance, a phenomenon known as Frank-Starlings law of the heart. At its basis is the ability of cardiac muscle to produce increased active force in response to increased muscle length. Although numerous studies have been conducted to elucidate the molecular basis of length-dependent activation, the mechanism remains elusive. The giant protein titin (also known as connectin) is the third filament system in the sarcomere and is responsible for most passive stiffness of striated muscle in the physiological sarcomere length range. The force generated by titin is usually seen as passive and independent of active force generation. Recent findings, however, suggest that titin-based passive force modulates actin-myosin interaction, resulting in greater active force in response to stretch. In this short review, we discuss the molecular mechanisms of length-dependent activation, focusing on the possible role of titin in its regulation.
Keywords: heart, cardiac muscle, frank-starling, sarcomere length, titin
Current Vascular Pharmacology
Title: Role of the Giant Elastic Protein Titin in the Frank-Starling Mechanism of the Heart
Volume: 2 Issue: 2
Author(s): Norio Fukuda and Henk Granzier
Affiliation:
Keywords: heart, cardiac muscle, frank-starling, sarcomere length, titin
Abstract: Increased ventricular volume enhances the systolic performance, a phenomenon known as Frank-Starlings law of the heart. At its basis is the ability of cardiac muscle to produce increased active force in response to increased muscle length. Although numerous studies have been conducted to elucidate the molecular basis of length-dependent activation, the mechanism remains elusive. The giant protein titin (also known as connectin) is the third filament system in the sarcomere and is responsible for most passive stiffness of striated muscle in the physiological sarcomere length range. The force generated by titin is usually seen as passive and independent of active force generation. Recent findings, however, suggest that titin-based passive force modulates actin-myosin interaction, resulting in greater active force in response to stretch. In this short review, we discuss the molecular mechanisms of length-dependent activation, focusing on the possible role of titin in its regulation.
Export Options
About this article
Cite this article as:
Fukuda Norio and Granzier Henk, Role of the Giant Elastic Protein Titin in the Frank-Starling Mechanism of the Heart, Current Vascular Pharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570161043476357
DOI https://dx.doi.org/10.2174/1570161043476357 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combining Stem Cells and Tissue Engineering in Cardiovascular Repair - a Step Forward to Derivation of Novel Implants with Enhanced Function and Self-Renewal Characteristics
Recent Patents on Cardiovascular Drug Discovery Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry “Connecting the Dots” from Blood Brain Barrier Dysfunction to Neuroinflammation and Alzheimer’s Disease
Current Neurovascular Research Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach
Current Drug Discovery Technologies The Immune System and the Brain: Crosstalk with a Broad Impact From Host Defense to Cognition
Current Neurovascular Research Vitamin D and Depression: The Evidence from an Indirect Clue to Treatment Strategy
Current Drug Targets Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall
Current Vascular Pharmacology Neuroprotection Against Ischemic / Hypoxic Brain Damage: Blockers of Ionotropic Glutamate Receptor and Voltage Sensitive Calcium Channels
Current Drug Targets Targeting the JNK Signaling Pathway for Stroke and Parkinsons Diseases Therapy
Current Drug Targets - CNS & Neurological Disorders Reliability of Blood Pressure Patterns Defined by a Single 24-Hour Ambulatory Blood Pressure Monitoring: The Case of the Dipping/Non Dipping and Isolated Clinic Hypertension
Current Hypertension Reviews Intensive Insulin Therapy in Critical Care Settings
Current Clinical Pharmacology A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury
Current Neuropharmacology Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Combined Treatment Modalities for Age Related Macular Degeneration
Current Drug Targets Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology